Will the recently approved LARES mission be able to measure the Lense-Thirring effect at 1%?

After the approval by the Italian Space Agency of the LARES satellite, which should be launched at the end of 2009 with a VEGA rocket and whose claimed goal is a about 1% measurement of the general relativistic gravitomagnetic Lense-Thirring effect in the gravitational field of the spinning Earth, it is of the utmost importance to reliably assess the total realistic accuracy that can be reached by such a mission. The observable is a linear combination of the nodes of the existing LAGEOS and LAGEOS II satellites and of LARES able to cancel out the impact of the first two even zonal harmonic coefficients of the multipolar expansion of the classical part of the terrestrial gravitational potential representing a major source of systematic error. While LAGEOS and LAGEOS II fly at altitudes of about 6000 km, LARES will be placed at an altitude of 1450 km. Thus, it will be sensitive to much more even zonals than LAGEOS and LAGEOS II. Their corrupting impact \delta\mu has been evaluated by using the standard Kaula's approach up to degree L=70 along with the sigmas of the covariance matrices of eight different global gravity solutions (EIGEN-GRACE02S, EIGEN-CG03C, GGM02S, GGM03S, JEM01-RL03B, ITG-Grace02s, ITG-Grace03, EGM2008) obtained by five institutions (GFZ, CSR, JPL, IGG, NGA) with different techniques from long data sets of the dedicated GRACE mission. It turns out \delta\mu about 100-1000% of the Lense-Thirring effect. An improvement of 2-3 orders of magnitude in the determination of the high degree even zonals would be required to constrain the bias to about 1-10%.Comment: Latex, 15 pages, 1 table, no figures. Final version matching the published one in General Relativity and Gravitation (GRG

An Assessment of the Systematic Uncertainty in Present and Future Tests of the Lense-Thirring Effect with Satellite Laser Ranging

We deal with the attempts to measure the Lense-Thirring effect with the Satellite Laser Ranging (SLR) technique applied to the existing LAGEOS and LAGEOS II terrestrial satellites and to the recently approved LARES spacecraft.The first issue addressed here is: are the so far published evaluations of the systematic uncertainty induced by the bad knowledge of the even zonal harmonic coefficients J_L of the multipolar expansion of the Earth's geopotential reliable and realistic? Our answer is negative. Indeed, if the differences Delta J_L among the even zonals estimated in different Earth's gravity field global solutions from the dedicated GRACE mission are assumed for the uncertainties delta J_L instead of using their covariance sigmas sigma_JL, it turns out that the systematic uncertainty \delta\mu in the Lense-Thirring test with the nodes Omega of LAGEOS and LAGEOS II may be up to 3 to 4 times larger than in the evaluations so far published ($5-10$) based on the use of the sigmas of one model at a time separately. The second issue consists of the possibility of using a different approach in extracting the relativistic signature of interest from the LAGEOS-type data. The third issue is the possibility of reaching a realistic total accuracy of 1% with LAGEOS, LAGEOS II and LARES, which should be launched in November 2009 with a VEGA rocket. While LAGEOS and LAGEOS II fly at altitudes of about 6000 km, LARES will be likely placed at an altitude of 1450 km. Thus, it will be sensitive to much more even zonals than LAGEOS and LAGEOS II. Their corrupting impact has been evaluated with the standard Kaula's approach up to degree L=60 by using Delta J_L and sigma_JL; it turns out that it may be as large as some tens percent.Comment: LaTex, 19 pages, 1 figure, 12 tables. Invited and refereed contribution to The ISSI Workshop, 6-10 October 2008, on The Nature of Gravity Confronting Theory and Experiment in Space To appear in Space Science Review

Phenomenology of the Lense-Thirring effect in the Solar System

Recent years have seen increasing efforts to directly measure some aspects of the general relativistic gravitomagnetic interaction in several astronomical scenarios in the solar system. After briefly overviewing the concept of gravitomagnetism from a theoretical point of view, we review the performed or proposed attempts to detect the Lense-Thirring effect affecting the orbital motions of natural and artificial bodies in the gravitational fields of the Sun, Earth, Mars and Jupiter. In particular, we will focus on the evaluation of the impact of several sources of systematic uncertainties of dynamical origin to realistically elucidate the present and future perspectives in directly measuring such an elusive relativistic effect.Comment: LaTex, 51 pages, 14 figures, 22 tables. Invited review, to appear in Astrophysics and Space Science (ApSS). Some uncited references in the text now correctly quoted. One reference added. A footnote adde

Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non-Small Cell Lung Cancer: A Phase I Trial.

Purpose : To establish the feasibility and tolerability of gefitinib (ZD1839, Iressa) with radiation (RT) or concurrent chemoradiation (CRT) with cisplatin (CDDP) in patients with advanced non small cell lung cancer (NSCLC).Patients and Methods : In this multicenter Phase I study, 5 patients with unresectable NSCLC received 250 mg gefitinib daily starting 1 week before RT at a dose of 63 Gy (Step 1). After a first safety analysis, 9 patients were treated daily with 250 mg gefitinib plus CRT in the form of RT and weekly CDDP 35 mg/m(2) (Step 2). Gefitinib was maintained for up to 2 years until disease progression or toxicity.Results : Fourteen patients were assessed in the two steps. In Step 1 (five patients were administered only gefitinib and RT), no lung toxicities were seen, and there was no dose-limiting toxicity (DLT). Adverse events were skin and subcutaneous tissue reactions, limited to Grade 1-2. In Step 2, two of nine patients (22.2%) had DLT. One patient suffered from dyspnea and dehydration associated with neutropenic pneumonia, and another showed elevated liver enzymes. In both steps combined, 5 of 14 patients (35.7%) experienced one or more treatment interruptions.Conclusions : Gefitinib (250 mg daily) in combination with RT and CDDP in patients with Stage HI NSCLC is feasible, but CDDP likely enhances toxicity. The impact of gefitinib on survival and disease control as a first-line treatment in combination with RT remains to be determined. (C) 2011 Elsevier Inc

Healthcare utilization and mortality among veterans of the Gulf War

The authors conducted an extensive search for published works concerning healthcare utilization and mortality among Gulf War veterans of the Coalition forces who served during the1990–1991 Gulf War. Reports concerning the health experience of US, UK, Canadian, Saudi and Australian veterans were reviewed. This report summarizes 15 years of observations and research in four categories: Gulf War veteran healthcare registry studies, hospitalization studies, outpatient studies and mortality studies. A total of 149 728 (19.8%) of 756 373 US, UK, Canadian and Australian Gulf War veterans received health registry evaluations revealing a vast number of symptoms and clinical conditions but no suggestion that a new unique illness was associated with service during the Gulf War. Additionally, no Gulf War exposure was uniquely implicated as a cause for post-war morbidity. Numerous large, controlled studies of US Gulf War veterans' hospitalizations, often involving more than a million veterans, have been conducted. They revealed an increased post-war risk for mental health diagnoses, multi-symptom conditions and musculoskeletal disorders. Again, these data failed to demonstrate that Gulf War veterans suffered from a unique Gulf War-related illness. The sparsely available ambulatory care reports documented that respiratory and gastrointestinal complaints were quite common during deployment. Using perhaps the most reliable data, controlled mortality studies have revealed that Gulf War veterans were at increased risk of injuries, especially those due to vehicular accidents. In general, healthcare utilization data are now exhausted. These findings have now been incorporated into preventive measures in support of current military forces. With a few diagnostic exceptions such as amyotrophic lateral sclerosis, mental disorders and cancer, it now seems time to cease examining Gulf War veteran morbidity and to direct future research efforts to preventing illness among current and future military personnel